The benefits of beta-blocker use extends to older people, even those with conditions that would lead them to be excluded from enrollment in randomized trials evaluating these agents. Dr. D.D. Sin and colleagues of the Department of Pulmonary Medicine (DDS), University of Alberta Hospital, Edmonton, Canada studied the effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 patients 65 years or older with heart failure. Mean age was 79 years and 49 percent of the patients were men. During a median of 21 months of follow-up, 3,539 patients were hospitalised for heart failure and 6,757 died. In total, 1,162 patients were treated with beta-blockers.
האם המהפכה הטיפולית בהשמנת יתר תפרוץ את חומת הכלכלה? פרופ' רז ופרופ' שטרן
לפניכם הרצאה ודיון שהתקיים בין פרופ’ איתמר רז ופרופ’ נפתלי שטרן בנושא השפעות החידושים הטיפוליים בתחום ההשמנה.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!